ACTRN12611001134910已完成1 期
Safety and efficacy of dendritic cell immunotherapy in patients with hepatitis C virus infection.
Eric J Gowans0 个研究点目标入组 6 人开始时间: 2011年10月31日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •HCV RNA positive for >6 months.
- •Previously failed interferon-based therapy.
- •Infected with genotype 1.
排除标准
- •Evidence of liver infection with other hepatitis agents, viz. HAV, HBV.
- •HIV infection.
- •Evidence of autoimmunity.
研究者
相似试验
已完成
1 期
A clinical study on the safety of dendritic cell vaccine pulsed with neoantigen peptides for malignant tumor.JPRN-UMIN000032981KOUSHIKAI,Non-profitmedicalcorporation5
招募中
不适用
Clinical trial evaluating dendritic cell vaccination as an adjuvant immunotherapy in patients with pancreatic cancerPancreatic cancerJPRN-UMIN000009994Yokohama City University, Gastroenterological Surgery20
尚未招募
不适用
Dendritic cell-based immunotherapy combined with low-dose cyclophosphamide in patients with malignant pleural mesotheliomamesothelioma10035597NL-OMON32554Erasmus MC, Universitair Medisch Centrum Rotterdam10
进行中（未招募）
不适用
Dendritic cell-based Immunotherapy in patients with primary glioblastoma multiformeNeoplasmsKCT0000280Bundang CHA General Hospital13
已完成
不适用
Dendritic cell-based immunotherapy for ovrian cancer patients.NeoplasmsKCT0000831Asan Medical Center10